Veradermics is trading at $110.42 (4.13% up) today. - The surge follows positive topline results from its Phase 2 clinical trial (Study '207') of VDPHL01 in females with mild-to-moderate pattern hair loss, announced on July 15, 2026. - The company also presented subgroup analysis data from its Phase 2/3 Study '302' in males on July 16-17, accompanied by analyst upgrades and increased price targets. - The stock's performance outpaces the broader biotech sector, which is down 2.04% today, amidst general positive sentiment for the biotech IPO market.